|
Edgar G. Engleman
Managing Partner
Dr. Engleman is a founding member of Vivo Ventures, LLC (formerly
BioAsia Investments).
Dr. Engleman is Professor of Pathology and Medicine at Stanford
University School of Medicine, where he oversees the Stanford Blood
Center and his own immunology research group. An editor of numerous
scientific journals and the inventor of multiple patented
technologies, Dr. Engleman has authored more than 250 publications
in medical and scientific journals and has trained more than 200
graduate students and postdoctoral fellows.
He has co-founded a number of biopharmaceutical companies including
Cetus Immune, Genelabs, National Medical Audit and Dendreon. He is
the lead inventor of the technology underlying Provenge, Dendreon's
cancer vaccine, which was shown to extend life for patients with
metastatic prostate cancer with remarkably few side effects.
Provenge is the first active immunotherapeutic agent to be approved
by the FDA (in 2010).
Dr. Engleman currently serves on the boards of several private
biotechnology companies. He received his B.A. from Harvard
University and his M.D. from Columbia University School of Medicine.
|
Our Team
Dr. Frank Kung
Dr. Edgar G. Engleman
Dr. Albert Cha
Dr. Chen Yu
James Huang, MBA
James Zhao, MD, MBA
Mahendra Shah, Ph.D.
|
